BioCentury This Week
Total duration:
17 h 25 min
Ep.232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data
BioCentury This Week
26:21
Bonus Content - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
BioCentury This Week
32:57
Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note
BioCentury This Week
25:03
Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
BioCentury This Week
31:41
Ep. 230 - Bio€quity Europe 2024 Preview
BioCentury This Week
25:50
Ep. 229 - ASGCT Preview, Accelerated Approval Plus: The Latest in Biosecure
BioCentury This Week
28:35
Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera
BioCentury This Week
23:02
Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss
BioCentury This Week
22:42
Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves
BioCentury This Week
22:59
Ep. 225 - 2Q Markets Preview & AACR Takeaways
BioCentury This Week
21:42
Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS
BioCentury This Week
21:11
Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs
BioCentury This Week
28:14
Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts
BioCentury This Week
20:48
Ep. 221 - China Biocontroversy, Plus: Diversity Matters
BioCentury This Week
31:52
Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight
BioCentury This Week
24:21
Ep. 219 - East-West Summit Preview
BioCentury This Week
25:29
Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases
BioCentury This Week
24:54
Ep. 217 - Safer CAR Ts & World’s First TIL Therapy
BioCentury This Week
24:57
Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond
BioCentury This Week
26:38
Ep. 215 - ADCs, Psychedelics & IPOs
BioCentury This Week
24:57
Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech
BioCentury This Week
29:44
Ep. 213 - Biotech IPOs & IL-18 Momentum
BioCentury This Week
28:06
Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact
BioCentury This Week
30:09
Ep. 211 - 2024 Markets Preview, Woodcock's Legacy
BioCentury This Week
22:17
Ep. 210 - J.P. Morgan Healthcare Conference Wrap
BioCentury This Week
27:27
Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024
BioCentury This Week
37:36
Ep. 208 - XBI Rally, ASH Highlights & '24 Picks
BioCentury This Week
24:00
Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in
BioCentury This Week
30:34
Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T
BioCentury This Week
19:57
Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech
BioCentury This Week
25:28
Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans
BioCentury This Week
29:02
Ep. 203 - POC for Verve? Plus: IRA & East-West Deals
BioCentury This Week
21:21
Ep. 202 - A DMD Decision & Endpoint Innovation
BioCentury This Week
30:27
Ep. 201 - ESMO, NIH & IRA
BioCentury This Week
17:56
Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors
BioCentury This Week
27:32
Ep. 199 - China Summit Preview
BioCentury This Week
23:47
Ep. 198 - Novartis Finds Focus & EU Pharma Law
BioCentury This Week
27:59
Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview
BioCentury This Week
28:32
Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi
BioCentury This Week
29:23
Ep. 195 - East-West Summit Preview
BioCentury This Week
19:53